乐观
$7.68
情景价格
$13.150
+0.359 (+2.73%)收盘时
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

InfuSystem Postpones Q3 Financial Results Release

InfuSystem to Host Investor Webcast on September 24, 2026

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

InfuSystem Reports Record Q2 2026 Revenue of $36.9 Million

InfuSystem Reports Increased Q2 Earnings and Revenue Growth
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。